Mistrust in China after the death of several babies, along with an expanding population and growing middle class, has led to surging demand for Western baby milk formula, presenting both an opportunity and a challenge to Swiss manufacturers. Last year, Nestlé bought Pfizer’s infant nutrition business for USD 12 billion (CHF 11 billion), a deal that increased its previously insipid Chinese market share overnight. The Swiss food manufacturing giant, which started out more than 100 years ago as a baby milk substitute specialist, is making a late charge at Chinese dominance after living in the shadow of international competitors in the last decade.